Metraipolis › archive › dc_ac6fa5861536

Serum Transthyretin as a Prognostic and Therapeutic Biomarker in Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis — Europe PMC PMID:42123087

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42123087
DOI
10.3390/jcm15093355
License (as archived)
solo-consultazione
Archived
2026-11-03T03:03:21.285Z
SHA-256 of the archived text
4b3e73da5b3138fb5e9690e274208418987003f3f9950ea6c5c73af369c311af
Stable URL of this page
https://metraipolis.com/documento/dc_ac6fa5861536

How to cite

Serum Transthyretin as a Prognostic and Therapeutic Biomarker in Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis — Europe PMC PMID:42123087 — Europe PMC (en), https://europepmc.org/article/MED/42123087 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ac6fa5861536 (Metraipolis archive dc_ac6fa5861536, sha256 4b3e73da5b3138fb5e9690e274208418987003f3f9950ea6c5c73af369c311af)
BibTeX
@misc{dcac6fa5861536,
  title = {Serum Transthyretin as a Prognostic and Therapeutic Biomarker in Transthyretin Amyloid Cardiomyopathy Patients Treated with Tafamidis — Europe PMC PMID:42123087},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42123087},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ac6fa5861536; sha256 4b3e73da5b3138fb5e9690e274208418987003f3f9950ea6c5c73af369c311af},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42123087. Agents can read the archived copy with the MCP tool read_document.